|
Post by mnholdem on Aug 5, 2015 7:31:33 GMT -5
I suspect this stock of Pfizer insulin will eventually be used in formulating Afrezza for countries where requisite pricing is much lower than the U.S. and where COGS will be tantamount to Sanofi. Also, several of these countries may not recognize the need for approval of human insulin from a different supplier. Sanofi markets and sells in 120 countries, so they'll know where (and when) the stock can be used up, IMHO.
|
|